Sphera Funds Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Sphera Funds Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-300,000	Closed	-$4.68M	–	158
2017 Q4	$4.68M	Hold	300,000	–	–	0.55%	47
2017 Q3	$3.33M	Hold	300,000	–	–	0.48%	56
2017 Q2	$2.76M	Hold	300,000	–	–	0.47%	65
2017 Q1	$2.56M	Buy	+300,000	New	+$2.73M	0.5%	60
2015 Q2	–	Sell	-80,957	Closed	-$1.17M	–	169
2015 Q1	$1.17M	Buy	+80,957	New	+$1.24M	0.12%	130

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Sphera Funds Management's STML Position: Q1 2018 in Review

Sphera Funds Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2018, closing a stake of 300,000 shares — an estimated $4.68M sold.

Sphera Funds Management first reported a position in STML in Q1 2015 and held it in 5 quarters. The position peaked at $4.68M in Q4 2017. 82 funds tracked by Wall St. Rank hold STML as of Q1 2018.

Sphera Funds Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Sphera Funds Management sold 300,000 Stemline Therapeutics, Inc. shares in Q1 2018, an estimated $4.68M.
Sphera Funds Management first reported a position in Stemline Therapeutics, Inc. in Q1 2015 and held it in 5 quarters.
Sphera Funds Management's Stemline Therapeutics, Inc. position peaked at $4.68M in Q4 2017.
82 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2018.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.